Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Receivables (2016 - 2025)

CorMedix has reported Receivables over the past 12 years, most recently at $171.2 million for Q4 2025.

  • Quarterly results put Receivables at $171.2 million for Q4 2025, up 231.5% from a year ago — trailing twelve months through Dec 2025 was $171.2 million (up 231.5% YoY), and the annual figure for FY2025 was $171.2 million, up 231.5%.
  • Receivables reached $171.2 million in Q4 2025 per CRMD's latest filing, up from $162.6 million in the prior quarter.
  • Across five years, Receivables topped out at $171.2 million in Q4 2025 and bottomed at $2975.0 in Q1 2022.
  • Median Receivables over the past 4 years was $957206.0 (2025), compared with a mean of $40.7 million.
  • The largest annual shift saw Receivables tumbled 93.18% in 2022 before it soared 5975.24% in 2025.
  • Over 4 years, Receivables stood at $45368.0 in 2021, then plummeted by 93.44% to $2975.0 in 2022, then skyrocketed by 1736168.91% to $51.7 million in 2024, then surged by 231.5% to $171.2 million in 2025.
  • Business Quant data shows Receivables for CRMD at $171.2 million in Q4 2025, $162.6 million in Q3 2025, and $42.9 million in Q2 2025.